SEARCH

SEARCH BY CITATION

References

  • 1
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin 2009; 59: 2259.
  • 2
    Harzstark AL, Ryan CJ. Novel therapeutic strategies in development for prostate cancer. Expert Opin Investig Drugs 2008; 17: 1322.
  • 3
    Shah N, Dizon DS. New-generation platinum agents for solid tumors. Future Oncol 2009; 5: 3342.
  • 4
    Giovagnini L, Ronconi L, Aldinucci D, Lorenzon D, Sitran S, Fregona D. Synthesis, characterization, and comparative in vitro cytotoxicity studies of platinum(II), palladium(II), and gold(III) methylsarcosinedithiocarbamate complexes. J Med Chem 2005; 48: 158895.
  • 5
    Milacic V, Chen D, Ronconi L, Landis-Piwowar KR, Fregona D, Dou QP. A novel anticancer gold(III) dithiocarbamate compound inhibits the activity of a purified 20S proteasome and 26S proteasome in human breast cancer cell cultures and xenografts. Cancer Res 2006; 66: 1047886.
  • 6
    Casini A, Kelter G, Gabbiani C, Cinellu MA, Minghetti G, Fregona D, Fiebig HH, Messori L. Chemistry, antiproliferative properties, tumor selectivity, and molecular mechanisms of novel gold(III) compounds for cancer treatment: a systematic study. J Biol Inorg Chem 2009; 14: 113949.
  • 7
    Aldinucci D, Ronconi L, Fregona D. Groundbreaking gold(III) anticancer agents. Drug Discov Today 2009; 14: 10756.
  • 8
    Ronconi L, Giovagnini L, Marzano C, Bettio F, Graziani R, Pilloni G, Fregona D. Gold dithiocarbamate derivatives as potential antineoplastic agents: design, spectroscopic properties, and in vitro antitumor activity. Inorg Chem 2005; 44: 186781.
  • 9
    Ronconi L, Fregona D. The Midas touch in cancer chemotherapy: from platinum- to gold-dithiocarbamato complexes. Dalton Trans 2009; 1067080.
  • 10
    Marzano C, Trevisan A, Giovagnini L, Fregona D. Synthesis of a new platinum(II) complex: anticancer activity and nephrotoxicity in vitro. Toxicol In Vitro 2002; 16: 439.
  • 11
    Marzano C, Bettio F, Baccichetti F, Trevisan A, Giovagnini L, Fregona D. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity. Chem-Biol Interact 2004; 148: 3748.
  • 12
    Saggioro D, Rigobello MP, Paloschi L, Folda A, Moggach SA, Parsons S, Ronconi L, Fregona D, Bindoli A. Gold(III)-dithiocarbamato complexes induce cancer cell death triggered by thioredoxin redox system inhibition and activation of ERK pathway. Chem Biol 2007; 14: 112839.
  • 13
    Chen G, Li A, Zhao M, Gao Y, Zhou T, Xu Y, Du Z, Zhang X, Yu X. Proteomic analysis identifies protein targets responsible for depsipeptide sensitivity in tumor cells. J Proteome Res 2008; 7: 273342.
  • 14
    Aldinucci D, Lorenzon D, Stefani L, Giovagnini L, Colombatti A, Fregona D. Antiproliferative and apoptotic effects of two new gold(III) methylsarcosine-dithiocarbamate derivatives on human acute myeloid leukemia cells in vitro. Anti-Cancer Drugs 2007; 18: 32332.
  • 15
    Nefedova Y, Landowski TH, Dalton WS. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia 2003; 17: 117582.
  • 16
    Campos CB, Paim BA, Cosso RG, Castilho RF, Rottenberg H, Vercesi AE. Method for monitoring of mitochondrial cytochrome-c release during cell death: immunodetection of cytochrome-c by flow cytometry after selective permeabilization of the plasma membrane. Cytometry A 2006; 69: 51523.
  • 17
    Liang CC, Park AY, Guan JL. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2007; 2: 32933.
  • 18
    Debatin KM. Apoptosis pathways in cancer and cancer therapy. Cancer Immunol Immunother 2004; 53: 1539.
  • 19
    Singh SS, Li Y, Ford OH,III Wrzosek CS, Mehedint DC, Titus MA, Mohler JL. Thioredoxin reductase 1 expression and castration-recurrent growth of prostate cancer. Transl Oncol 2008; 1: 1537.
  • 20
    Bonaccorsi L, Marchiani S, Muratori M, Carloni V, Forti G, Baldi E. Signaling mechanisms that mediate invasion in prostate cancer cells. Ann NY Acad Sci 2004; 1028: 2838.
  • 21
    Bonaccorsi L, Muratori M, Carloni V. The androgen receptor associates with the epidermal growth factor receptor in androgen-sensitive prostate cancer cells. Steroids 2004; 69: 54952.
  • 22
    Kostova I. Gold coordination complexes as anticancer agents. Anti-Cancer Agents Med Chem 2006; 6: 1932.
  • 23
    Gabbiani C, Casini A, Messori L. Gold(III) compounds as anticancer drugs. Gold Bull 2007; 40: 7388.
  • 24
    Tiekink ERT. Anti-cancer potential of gold complexes. Inflammopharmacology 2008; 16: 13842.
  • 25
    Ott I. On the medicinal chemistry of gold complexes as anticancer drugs. Coord Chem Rev 2009; 253: 167081.
  • 26
    Nobili S, Mini E, Landini I, Gabbiani C, Casini A, Messori L. Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies. Med Res Rev, DOI 10.1002/med.20168
  • 27
    Brunelle JK, Letai A. Control of mitochondrial apoptosis by the Bcl-2 family. J Cell Sci 2009; 122: 43741.
  • 28
    Kang MH, Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 2009; 15: 112632.
  • 29
    Tonissen KF, Di Trapani G. Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy. Mol Nutr Food Res 2009; 53: 87103.
  • 30
    Lincoln DT, Ali Emadi EM, Tonissen KF, Clarke FM. The thioredoxin-thioredoxin reductase system: overexpression in human cancer. Anticancer Res 2003; 23: 242534.
  • 31
    Sun Y, Rigas B. The thioredoxin system mediates redox-induced cell death in human colon cancer cells: implications for the mechanism of action of anticancer agents. Cancer Res 2008; 68: 826977.
  • 32
    Yamada M, Tomida A, Yoshikawa H, Taketani Y, Tsuruo T. Increased expression of thioredoxin/adult T-cell leukemia-derived factor in cisplatin-resistant human cancer cell lines. Clin Cancer Res 1996; 2: 42732.
  • 33
    Kim SJ, Miyoshi Y, Taguchi T, Tamaki Y, Nakamura H, Yodoi J, Kato K, Noguchi S. High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer. Clin Cancer Res 2005; 11: 842530.
  • 34
    Powis G, Kirkpatrick DL. Thioredoxin signaling as a target for cancer therapy. Curr Opin Pharmacol 2007; 7: 3927.
  • 35
    Rackham O, Nichols SJ, Leedman PJ, Berners-Price SJ, Filipovska A. A gold(I) phosphine complex selectively induces apoptosis in breast cancer cells: implications for anticancer therapeutics targeted to mitochondria. Biochem Pharmacol 2007; 74: 9921002.
  • 36
    Bonaccorsi L, Marchiani S, Muratori M, Forti G, Baldi E. Gefitinib (‘IRESSA’, ZD1839) inhibits EGF-induced invasion in prostate cancer cells by suppressing PI3 K/AKT activation. J Cancer Res Clin Oncol 2004; 130: 60414.
  • 37
    Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Autorino R, D'Armiento M, De Laurentiis M, De Placido S, Catalano G, Bianco AR, Ciardiello F. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 2002; 8: 343844.
  • 38
    Schlomm T, Kirstein P, Iwers L, Daniel B, Steuber T, Walz J, Chun FHK, Haese A, Kollermann J, Graefen M, Huland H, Sauter G, Simon R, Erbersdobler A. Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer. Clin Cancer Res 2007; 13: 657984.
  • 39
    Bratland A, Boender PJ, Høifødt HK. Osteoblast-induced EGFR/ERBB2 signaling in androgen-sensitive prostate carcinoma cells characterized by multiplex kinase activity profiling. Clin Exp Metastasis 2009; 26: 48596.